On June 10, 2025, FDA Commissioner Martin A. Makary and Chief Medical and Science Officer Vinay Prasad published an article in the Journal of the American Medical Association titled, “Priorities for a New FDA.”1 The article...more
6/25/2025
/ Artificial Intelligence ,
Biosimilars ,
Drug Pricing ,
Food and Drug Administration (FDA) ,
Healthcare Reform ,
New Regulations ,
Popular ,
Prescription Drugs ,
Public Health ,
Regulatory Reform ,
Regulatory Requirements
The Inflation Reduction Act (the Act) of 2022 was controversial at the time the Act was signed into law and remains so. To date, multiple legal challenges have been asserted against the Act, with more expected in the future....more